Key result
Drug-drug interactions involving antiplatelet drugs, particularly with anticoagulants, NSAIDs, and PPIs, increase bleeding risk and reduce efficacy in patients with atherosclerotic vascular disease.
Why the study?
Patients with atherosclerotic vascular disease often require multiple medications due to complex comorbidities, increasing the risk of drug-drug interactions that can lead to drug resistance, reduced efficacy, or adverse effects.
Population
Patients with atherosclerotic vascular disease receiving antiplatelet therapy
Design
Systematic literature review
Authors
Loading...
Clinicians should screen for DDIs with antiplatelets to limit bleeding; confirms risks with anticoagulants, NSAIDs, and PPIs in atherosclerotic disease.
Systematic Review
Drug-drug interactions with antiplatelet therapy, particularly involving anticoagulants, NSAIDs, and PPIs, significantly impact treatment efficacy and safety, highlighting the need for personalized management strategies.
Huang et al. (2025) conducted a systematic review in Atherosclerotic vascular disease. Drug-drug interactions in antiplatelet therapy was evaluated. Drug-drug interactions involving antiplatelet drugs, particularly with anticoagulants, NSAIDs, and PPIs, increase bleeding risk and reduce efficacy in patients with atherosclerotic vascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: